Fiche personne
Coordonnées
Centre Georges-François Leclerc
1 rue du Professeur Marion
BP 77980
21000 DIJON
03 80 73 75 18
Territoire
Bourgogne
Statut
Hospitalier
Affiliation
Équipes/plateformes
Recherche
Expertises :
- Clinique:Radiothérapie
Publications
Adjuvant radiotherapy in patients with pathological high-risk bladder cancer: Acute toxicity results from a randomized multicentre phase II trial (Bladder-ART/GETUG-AFU30).
Sargos P, Pignot G, Bellera C, Pommier P, Martin E, Clavere P, Hennequin C, Hoepffner JL, Marcq G, Roumiguié M, Crouzet S, Cormier L, Schartner V, Huchet N, Pasquier D, Khalifa J
Radiother Oncol. 2025 12 9;214:111326
Radiotherapy for primary lung cancer: 2025 update.
Khalifa J, El Houat Y, Thureau S, Darréon J, Antoni D, Blais E, Le Péchoux C, Lerouge D, Levy A, Lucia F, Marguerit A, Martin É, Pichon B, Pourel N, Giraud P, Riet FG
Cancer Radiother. 2025 11 27;29(7-8):104779
Radiotherapy for lung metastases.
Levy A, Tonneau M, Darréon J, Khalifa J, Antoni D, Blais E, Le Péchoux C, Lerouge D, Lucia F, Marguerit A, Martin É, Pichon B, Pourel N, Riet FG, Giraud P, Thureau S
Cancer Radiother. 2025 11 11;29(7-8):104760
Salvage brachytherapy for locally recurrent prostate cancer after definitive radiotherapy - a multicentric French cohort by the SFRO brachytherapy group.
Kissel M, Ka K, Meraouna Y, Terlizzi M, Schiappa R, Hannoun-Levi JM, Hanaya S, Serre AA, Sarr O, Verry C, Khoukaz A, Martin E, Cosset JM, Blanchard P
Radiother Oncol. 2025 09 30;213:111170
Surgery for all patients with T1N0 non-small cell lung cancer?
Pouypoudat C, Thureau S, Giraud N, Belaroussi Y, Martin É
Cancer Radiother. 2025 08 11;29(5-6):104683
[Recommendations on the prevention and management of radiation-induced lung injury from the Association francophone pour les soins oncologiques de support and the Société française de radiothérapie oncologique].
Cravéreau O, Bourbonne V, Vaugier L, Lucia F, Le Tinier F, Cadranel J, Duchemann B, Habert P, Martz N, Gehin W, Bruand M, Stefani A, Marcel J, Trampetti I, Clément-Duchêne C, Lerouge D, Laville A, Cao K, Pourel N, Zaccariotto A, Bellière-Calendry A, Thillays F, Tanguy R, Antoni D, Girard N, Martin É, Godbert B, Nakad A, Treffel G, Massin M, Charzat V, Thureau S, Lapierre A, Faivre JC
Cancer Radiother. 2025 08 6;29(5-6):104687
AFSOS-SFRO Guidelines on Radiation-Induced Lung Injury.
Cravereau O, Bourbonne V, Vaugier L, Lucia F, Tinier FL, Cadranel J, Duchemann B, Habert P, Martz N, Gehin W, Bruand M, Stefani A, Marcel J, Trampetti I, Clement-Duchene C, Lerouge D, Laville A, Cao K, Pourel N, Zaccariotto A, Belliere-Calendry A, Thillays F, Tanguy R, Antoni D, Girard N, Martin E, Godbert B, Nakad A, Treffel G, Massin M, Charzat V, Thureau S, Lapierre A, Faivre JC
Clin Lung Cancer. 2025 07 17;:
Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer.
Vera P, Giraud P, Hapdey S, Gouel P, Jan O, Le Roux P, Langlais A, Lévêque E, Le Tinier F, Olivier A, Martin E, Berriolo-Riedinger A, Pourel N, Broglia JM, Boisselier P, Guillemard S, Salem N, Brenot-Rossi I, Garcia C, Berthold C, Giroux-Leprieur E, Moreau D, Guillerm S, Benali K, Tessonnier L, Audigier-Valette C, Lerouge D, Quak E, Massabeau C, Courbon F, Loo M, Larrouy A, Ghazzar N, Chaumet-Riffaud P, Amour E, Zalcman G, Modzelewski R, Thureau S
J Nucl Med. 2025 02 27;:
Patterns of relapse following radiotherapy of intermediate-risk (IR) prostate cancer (PCa) on the PROFIT randomized trial.
Langé M, Campion L, Ollivier L, Renouf M, Magné N, Latorzeff I, Pommier P, Martin E, Paumier A, Bera G, Catton C, Martin J, Supiot S
Int J Radiat Oncol Biol Phys. 2025 02 4;:
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial.
Vera P, Thureau S, Le Tinier F, Chaumet-Riffaud P, Hapdey S, Kolesnikov-Gauthier H, Martin E, Berriolo-Riedinger A, Pourel N, Broglia JM, Boissellier P, Guillemard S, Salem N, Brenot-Rossi I, Le Péchoux C, Berthold C, Giroux-Leprieur E, Moreau D, Guillerm S, Benali K, Tessonnier L, Audigier-Valette C, Lerouge D, Quak E, Massabeau C, Courbon F, Moisson P, Larrouy A, Modzelewski R, Gouel P, Ghazzar N, Langlais A, Amour E, Zalcman G, Giraud P
Lancet Oncol. 2024 08 9;:
Recommendations for Post-Operative Radiotherapy after complete resection of Thymoma - a French DELPHI consensus initiative.
Basse C, Khalifa J, Thillays F, Le Pechoux C, Maury JM, Bonte PE, Coutte A, Pourel N, Bourbonne V, Pradier O, Belliere A, Le Tinier F, Deberne M, Tanguy R, Denis F, Padovani L, Zaccariotto A, Molina T, Chalabreysse L, Brioude G, Delatour B, Faivre JC, Cao K, Giraud P, Riet FG, Thureau S, Antoni D, Massabeau C, Keller A, Bonnet E, Lerouge D, Martin E, Girard N, Botticella A
J Thorac Oncol. 2024 04 10;:
Profiles, diagnostic process, and patterns of care of patients with stage III non-small cell lung cancer: A French national study.
Auliac JB, Greillier L, Martin E, Falcoz PE, Boisselier P, Ano S, Lefrançois M, Cortot A
Respir Med Res. 2024 01 23;85:101087
Immune changes in hilar tumor draining lymph nodes following node sparing neoadjuvant chemoradiotherapy of localized cN0 non-small cell lung cancer.
Khalifa J, Thébault N, Scarlata CM, Norkowski E, Massabeau C, Brouchet L, Peries Bataille S, Casaroli C, Vaz L, Valle C, Sarot E, Saint-Laurent N, Martin E, Pages PB, Millière A, Mazières J, Cohen-Jonathan Moyal E, Lauzéral-Vizcaïno F, Ayyoub M
Front Oncol. 2023 11 22;13:1269166
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C
BMC Cancer. 2023 11 9;23(1):1080
Radiotherapy in the management of synchronous metastatic lung cancer.
Khalifa J, Lévy A, Sauvage LM, Thureau S, Darréon J, Le Péchoux C, Lerouge D, Pourel N, Antoni D, Blais E, Martin É, Marguerit A, Giraud P, Riet FG
Cancer Radiother. 2023 08 11;:
[Stereotactic radiotherapy for operable stage I non-small cell lung cancer].
Martin É, Nicolet C, Boisselier P, Khalifa J, Thureau S
Cancer Radiother. 2023 08 8;:
Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer.
Levy A, Khalifa J, Martin E, Botticella A, Quevrin C, Lavaud P, Aldea M, Besse B, Planchard D, Barlesi F, Deutsch E, Massabeau C, Doyen J, Le Péchoux C
Clin Transl Radiat Oncol. 2023 07;41:100637
Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol.
Rogé M, Pointreau Y, Sargos P, Meyer E, Schick U, Hasbini A, Rio E, Bera G, Ruffier A, Quivrin M, Chasseray M, Latorzeff I, Martin E, Guimas V, Pommier P, Leroy T, Ronchin P, Lepinoy A, Grand A, Cartier L, Didas O, Denis F, Libois V, Blanc-Lapierre A, Supiot S
Clin Transl Radiat Oncol. 2023 05;40:100613
Prostatectomy Bed Image-guided Dose-escalated Salvage Radiotherapy (SPIDER): An International Multicenter Retrospective Study.
Benziane-Ouaritini N, Zilli T, Giraud A, Ingrosso G, Di Staso M, Trippa F, Pommier P, Meyer E, Francolini G, Schick U, Pasquier D, Marc Cosset J, Magne N, Martin E, Gnep K, Renard-Penna R, Anger E, Achard V, Giraud N, Aristei C, Ferrari V, Pasquier C, Zaine H, Osman O, Detti B, Perennec T, Mihoci I, Supiot S, Latorzeff I, Sargos P
Eur Urol Oncol. 2023 04 12;:
Elevated Baseline Neutrophil Count Correlates with Worse Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Chemoradiation.
Meunier S, Frontczak A, Balssa L, Blanc J, Benhmida S, Pernot M, Quivrin M, Martin E, Hammoud Y, Créhange G, Boustani J
Cancers (Basel). 2023 03 21;15(6):
Reaching multidisciplinary consensus on the management of non-bulky/non-infiltrative stage IIIA N2 non-small cell lung cancer.
Scherpereel A, Martin E, Brouchet L, Corre R, Duruisseaux M, Falcoz PE, Giraud P, Le Péchoux C, Wislez M, Alifano M
Lung Cancer. 2023 01 18;177:21-28
Outcomes following brachytherapy boost for intermediate- and high-risk prostate cancer: a retrospective bicenter study by the SFRO Brachytherapy Group.
Ka K, Schiappa R, Terlizzi M, Mallet F, Martin E, Chand ME, Demogeot N, Peiffert D, Pommier P, Quivrin M, Kissel M, Pasquier C, Khalifa J, Hannoun-Levi JM, Blanchard P
Radiother Oncol. 2023 01 10;:109460
Prediction of prostate cancer recurrence after radiation therapy using multiparametric magnetic resonance imaging and spectroscopy: assessment of prognostic factors on pretreatment imaging.
Asuncion A, Walker PM, Bertaut A, Blanc J, Labarre M, Martin E, Bardet F, Cassin J, Cormier L, Crehange G, Loffroy R, Cochet A
Quant Imaging Med Surg. 2022 12;12(12):5309-5325
[Stereotactic radiotherapy for localized primary lung tumours of stage T1-T2].
Boisselier P, Coutte A, Martin E, Pointreau Y
Cancer Radiother. 2022 09 5;:
Salvage Involved-Field and Extended-Field Radiation Therapy in Positron Emission Tomography-Positive Nodal Recurrent Prostate Cancer: Outcomes and Patterns of Failure.
Pêtre A, Quivrin M, Briot N, Boustani J, Martin E, Bessieres I, Cochet A, Créhange G
Adv Radiat Oncol. 2022 07 28;8(1):101040
[Intermediate-risk prostate cancer treated with exclusive external irradiation: Focus on anatomical sites of recurrence in two French trials].
Langé M, Magné N, Zhou K, Bellanger M, Latorzeff I, Pommier P, Martin E, Paumier A, Béra G, Supiot S
Cancer Radiother. 2022 06 14;:
Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy.
Di Meglio A, Havas J, Gbenou AS, Martin E, El-Mouhebb M, Pistilli B, Menvielle G, Dumas A, Everhard S, Martin AL, Cottu PH, Lerebours F, Coutant C, Lesur A, Tredan O, Soulie P, Vanlemmens L, Joly F, Delaloge S, Ganz PA, André F, Partridge AH, Jones LW, Michiels S, Vaz-Luis I
J Clin Oncol. 2022 Apr 21;:JCO2100277
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A,
Lancet. 2022 Apr 8;:
Prostate cancer brachytherapy: SFRO guidelines 2021.
Pommier P, Ferré M, Blanchard P, Martin É, Peiffert D, Robin S, Hannoun-Lévi JM, Marchesi V, Cosset JM
Cancer Radiother. 2021 Dec 22;:
Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood.
Boustani J, Joseph ELM, Martin E, Benhmida S, Lecoester B, Tochet F, Mirjolet C, Chevalier C, Thibouw D, Vulquin N, Servagi S, Sun X, Adotévi O
BMC Immunol. 2021 Jun 18;22(1):38
Unhealthy behaviors after breast cancer: Capitalizing on a teachable moment to promote lifestyle improvements.
Di Meglio A, Gbenou AS, Martin E, Pistilli B, Ligibel JA, Crane TE, Flaysakier JD, Minvielle E, Vanlemmens L, Guenancia C, Rigal O, Fournier M, Soulie P, Mouret-Reynier MA, Tarpin C, Boiffard F, Guillermet S, Everhard S, Martin AL, Giacchetti S, Petit T, Dalenc F, Rouanet P, Arnaud A, Andre F, Vaz-Luis I
Cancer. 2021 Apr 22;:
[Lung cancer and pulmonary metastasis treated by stereotactic radiosurgery: Evaluation of the relevance of realisation of 3 4D CT by the RPM technique].
Khadige M, Peiffert D, Buchheit I, Salleron J, Peignaux-Casasnovas K, Bidault F, Martin E
Cancer Radiother. 2020 Dec 26;:
Radiotherapy for primary tumor in lung cancer with synchronous metastases: Overview from the past and proposal for the future.
Laurent PA, Martin E, Thariat J, Doyen J
Cancer Radiother. 2020 Aug 19;:
Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancer.
Kaderbhaï CG, Coudert B, Bertaut A, Adnet J, Favier L, Lagrange A, Peignaux-Casasnovas K, Mettey L, Tharin Z, Foucher P, Martin E
Cancer Radiother. 2020 May 18;:
An exceptional metaplastic lobular breast carcinoma diagnosed through exome sequencing.
Bergeron A, Desmoulins I, Beltjens F, Causeret S, Charon-Barra C, Martin E, Richard C, Boidot R, Arnould L
J. Clin. Pathol.. 2020 Jan 24;:
Patterns of Bone Failure in Localized Prostate Cancer Previously Irradiated: The Preventive Role of External Radiotherapy on Pelvic Bone Metastases.
Grapin M, Quivrin M, Bertaut A, Martin E, Cormier L, Ladoire S, Cochet A, Créhange G
Front Oncol. 2019 ;9:70
Salvage extended field or involved field nodal irradiation in F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer.
Lépinoy A, Silva YE, Martin E, Bertaut A, Quivrin M, Aubignac L, Cochet A, Créhange G
Eur. J. Nucl. Med. Mol. Imaging. 2018 Sep 28;:
Inferring postimplant dose distribution of salvage permanent prostate implant (PPI) after primary PPI on CT images.
Girum KB, Lalande A, Quivrin M, Bessières I, Pierrat N, Martin E, Cormier L, Petitfils A, Cosset JM, Créhange G
Brachytherapy. 2018 Sep 11;:
Salvage brachytherapy as a modern reirradiation technique for local cancer failure: The Phoenix is reborn from its ashes.
Quivrin M, Peignaux-Casasnovas K, Martin É, Rouffiac M, Thibouw D, Chevalier C, Vulquin N, Aubignac L, Truc G, Créhange G
Cancer Radiother. 2018 May 30;:
Impact of rectal distension on prostate CBCT-based positioning assessed with 6 degrees-of-freedom couch.
Charret J, Salleron J, Quivrin M, Mazoyer F, Lesueur P, Martin E, Peiffert D, Créhange G
Pract Radiat Oncol. 2018 Mar 9;:
Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients.
Goineau A, Campion L, d'Aillières B, Vié B, Ghesquière A, Béra G, Jaffres D, de Laroche G, Magné N, Artignan X, Chamois J, Bergerot P, Martin E, Créhange G, Deniaud-Alexandre E, Buthaud X, Belkacémi Y, Doré M, de Decker L, Supiot S
PLoS ONE. 2018 ;13(4):e0194173
Phase II study of a radiotherapy total dose increase in hypoxic lesions identified by F-miso PET/CT in patients with non-small cell lung carcinoma [RTEP5 study].
Vera P, Thureau S, Chaumet-Riffaud P, Modzelewski R, Bohn P, Vermandel M, Hapdey S, Pallardy A, Mahé MA, Lacombe M, Boisselier P, Guillemard S, Olivier P, Beckendorf V, Salem N, Charrier N, Chajon E, Devillers A, Aide N, Danhier S, Denis F, Muratet JP, Martin E, Berriolo-Riedinger A, Kolesnikov-Gauthier H, Dansin E, Massabeau C, Courbon F, Farcy-Jacquet MP, Kotzki PO, Houzard C, Mornex F, Vervueren L, Paumier A, Fernandez P, Salaun M, Dubray B
J. Nucl. Med.. 2017 Mar;:
Safety and efficacy of intensity-modulated radiotherapy in the management of spermatic cord sarcoma.
Cerda T, Martin É, Truc G, Créhange G, Maingon P
Cancer Radiother. 2017 Feb;21(1):16-20
Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model.
Mirjolet C, Boudon J, Loiseau A, Chevrier S, Boidot R, Oudot A, Collin B, Martin E, Joy PA, Millot N, Créhange G
Int J Nanomedicine. 2017 ;12:6357-6364
Absolute volume of the rectum and AUC from rectal DVH between 25Gy and 50Gy predict acute gastrointestinal toxicity with IG-IMRT in prostate cancer.
Mirjolet C, Walker PM, Gauthier M, Dalban C, Naudy S, Mazoyer F, Martin E, Maingon P, Créhange G
Radiat Oncol. 2016 Nov;11(1):145
[Non-metastatic triple-negative breast cancer in 2016: Definitions and management].
Portha H, Jankowski C, Cortet M, Desmoulins I, Martin E, Lorgis V, Arnould L, Coutant C
Gynecol Obstet Fertil. 2016 Sep;44(9):492-504
Time interval between surgery and start of adjuvant radiotherapy in patients with soft tissue sarcoma: A retrospective analysis of 1131 cases from the French Sarcoma Group.
Fourquet J, Sunyach MP, Vilotte F, Le Péchoux C, Ranchère-Vince D, Bonvalot S, Coindre JM, Terrier P, Meeus P, Helfre S, Martin E, Vogin G, Biau J, Kao W, Noel G, Ducassou A, Llacer-Moscardo C, Stoeckle E, Penel N, Sargos P
Radiother Oncol. 2016 Jul;120(1):156-62
Multiparametric MRI and post implant CT-based dosimetry after prostate brachytherapy with iodine seeds: The higher the dose to the dominant index lesion, the lower the PSA bounce.
Quivrin M, Loffroy R, Cormier L, Mazoyer F, Bertaut A, Chambade D, Martin E, Maingon P, Walker P, Crehange G
Radiother Oncol. 2015 Aug 28. pii: S0167-8140(15)00445-4
[Surgery alone or in association with preoperative uterovaginal brachytherapy for stage IB1 cervical cancer: Toxicities profiles].
Lamblin G, Rouffiac M, Mathevet P, Martin E, Peignaux-Casasnovas K, Chabert P, Lebail-Carval K, Chene G
Gynecol Obstet Fertil. 2015 May 15. pii: S1297-9589(15)00122-8
Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
Crehange G, Roach M 3rd, Martin E, Cormier L, Peiffert D, Cochet A, Chapet O, Supiot S, Cosset JM, Bolla M, Chung HT
Cancer Radiother. 2014 Oct;18(5-6):524-34
[Radiological evaluation of the tumour response after lung stereotactic radiotherapy].
Vulquin N, Feutray S, Peignaux-Casasnovas K, Humbert O, Crehange G, Truc G, Maingon P, Martin E
Cancer Radiother. 2014 Oct;18(5-6):414-9
Image-guided IMRT for localized prostate cancer with daily repositioning: inferring the difference between planned dose and delivered dose distribution.
Arnaud A, Maingon P, Gauthier M, Naudy S, Dumas JL, Martin E, Peignaux-Casasnovas K, Truc G, Bonnetain F, Crehange G
Phys Med. 2014 Sep;30(6):669-75
Pattern of occult nodal relapse diagnosed with (18)F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only radiotherapy.
Lepinoy A, Cochet A, Cueff A, Cormier L, Martin E, Maingon P, Bosset JF, Brunotte F, Crehange G
Radiother Oncol. 2014 Apr;111(1):120-5
Study of dental prostheses influence in radiation therapy.
De Conto C, Gschwind R, Martin E, Makovicka L
Phys Med. 2014 Feb;30(1):117-21
Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2.
Derbal-Wolfrom L, Pencreach E, Saandi T, Aprahamian M, Martin E, Greferath R, Tufa E, Choquet P, Lehn JM, Nicolau C, Duluc I, Freund JN
Oncogene. 2013 Sep 5;32(36):4313-8
Regulation of the tumor suppressor homeogene Cdx2 by HNF4alpha in intestinal cancer.
Saandi T, Baraille F, Derbal-Wolfrom L, Cattin AL, Benahmed F, Martin E, Cardot P, Duclos B, Ribeiro A, Freund JN, Duluc I
Oncogene. 2013 Aug 8;32(32):3782-8
Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer.
Crehange G, Mirjolet C, Gauthier M, Martin E, Truc G, Peignaux-Casasnovas K, Azelie C, Bonnetain F, Naudy S, Maingon P
Radiother Oncol. 2012 May;103(2):244-6
Exclusive image-guided IMRT versus radical prostatectomy followed by postoperative IMRT for localized prostate cancer: A matched-pair analysis based on risk groups.
Azelie C, Gauthier M, Mirjolet-Didelot C, Cormier L, Martin E, Peignaux-Casasnovas K, Truc G, Maingon P, Crehange G
J. Clin. Oncol.. 2012 Feb;30(5_suppl):135
MR spectroscopy compared with DW-MRI and DCE-MRI at 3-tesla for the noninvasive prediction of short-term radiation response for patients with localized prostate cancer.
Crehange G, Maingon P, Gauthier M, Cochet A, Martin E, Mirjolet-Didelot C, Cormier L, Bonnetain F, Vignon N, Brunotte F, Walker PM
J. Clin. Oncol.. 2012 Feb;30(5_suppl):122
Use of the slope of the DVH curve for predicting late rectal toxicity in IMRT for patients with localized prostate cancer.
Crehange G, Walker PM, Gauthier M, Mirjolet-Didelot C, Petitfils A, Martin E, Chamois J, Khoury C, Maingon P
J. Clin. Oncol.. 2012 Feb;30(5_suppl):230
Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups.
Azelie C, Gauthier M, Mirjolet C, Cormier L, Martin E, Peignaux-Casasnovas K, Truc G, Chamois J, Maingon P, Crehange G
Radiat Oncol. 2012 Sep 17;7:158
Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.
Ladoire S, Eymard JC, Zanetta S, Mignot G, Martin E, Kermarrec I, Mourey E, Michel F, Cormier L, Ghiringhelli F
Anticancer Res. 2010 Oct;30(10):4317-23.
